The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040Takanori Ito, Mindie H. Nguyen, Masatoshi Ishigami et al.|Hepatology International|2021Cited by 151
Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver diseaseErina Kumagai, Tatsuya Kanto, Yohei Mano et al.|Scientific Reports|2016Cited by 105
Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver diseaseHirotaka Shoji, Tatsuya Kanto, Sachiyo Yoshio et al.|Scientific Reports|2016Cited by 64
Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysisAndrea Casadei‐Gardini, Alessandro Cucchetti, Mario Scartozzi et al.|Liver International|2021Cited by 60
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular CarcinomaMakoto Chuma, Shin Maeda, Haruki Uojima et al.|Cancers|2020Cited by 54